ArticleScientific reports2026
Liposomal encapsulation of L-arginine and L-citrulline enhances pharmacokinetics and therapeutic effects in a model of preeclampsia and fetal growth restriction.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
L-arginine and L-citrulline improve vascular health in preeclampsia (PE) and fetal growth restriction (FGR), but their short half-life limits efficacy. This study evaluated pharmacokinetics, delivery, and therapeutic outcomes of liposomal encapsulation of these amino acids in a rat model of PE and FGR. Pharmacokinetics of liposome-encapsulated L-arginine were compared with free L-arginine (Free L-arg) in normal pregnant (NP) dams. Therapeutic effect on maternal blood pressure and fetal weight were studied in NP rats and the reduced uterine perfusion pressure (RUPP) model. Treatment groups received Encapsulated L-arginine and L-citrulline (Encapsulated AAs); ratio 1:1, Free L-arginine and L-citrulline (AAs), or PBS. Blood and organs were analyzed for amino acid concentrations and liposome distribution. Nitrite and nitrate were measured to assess endogenous nitric oxide production in the pharmacokinetic study. Encapsulation increased blood arginine exposure > 120-fold and increased plasma and placental concentrations than free forms. In RUPP, Encapsulated AAs reduced maternal blood pressure without affecting fetal weight. Both encapsulated groups developed splenomegaly. Liposomal encapsulation markedly improved pharmacokinetics and placental delivery, thereby reducing maternal hypertension. However, it provided limited benefit for FGR. Optimized encapsulated AAs may represent a promising therapeutic strategy for PE and FGR, although the maternal splenomegaly observed requires further investigation before clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.